US FDA Grants Accelerated Approval to Gilead’s Livdelzi (Seladelpar) to Treat Primary Biliary Cholangitis (PBC)
Shots:
- Gilead’s Livdelzi (Seladelpar) as monotx. or in combination with ursodeoxycholic acid (UDCA) has received accelerated approval for adults unable to tolerate UDCA or with inadequate response to UDCA, respectively. Not recommended for individuals with decompensated cirrhosis
- The approval was based on a P-III (RESPONSE) study showing 62% vs 20% (Livdelzi vs PBO) composite biochemical response at 12mos.; normalization of ALP value in 25% Livdelzi pts at 12mos.
- For complete approval, confirmatory long-term study P-III (AFFIRM) has been initiated to evaluate Livdelzi's effect in compensated cirrhosis patients due to PBC. Seladelpar’s review has been accepted by MHRA and EMA
Ref: Gilead | Image: Gilead
Related News:- Gilead Reports Data from the P-III (ASSURE) Trial of Seladelpar for Treating Primary Biliary Cholangitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
